{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:55Z","timestamp":1786988035785,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114129","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T12:11:21Z","timestamp":1716639081000},"page":"114129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas"],"prefix":"10.1016","volume":"208","author":[{"given":"Alberto","family":"Bongiovanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Liverani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Foca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Meglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Marconcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Recine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Tebaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Severi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Rudnas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Ranallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Crudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.114129_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","article-title":"Neuroendocrine tumors, version 1.2015","volume":"13","author":"Kulke","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"10.1016\/j.ejca.2024.114129_bib2","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jnci\/djn275","article-title":"Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors","volume":"100","author":"Modlin","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ejca.2024.114129_bib3","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114129_bib4","unstructured":"WHO Classification of Tumours Editorial Board: 2022 WHO classification of endocrine and neuroendocrine tumours. Lyon, France, IARC, 2022."},{"issue":"7","key":"10.1016\/j.ejca.2024.114129_bib5","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/ERC-19-0483","article-title":"Extrapulmonary poorly differentiated NECs, including molecular and immune aspects","volume":"27","author":"McNamara","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.114129_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.114129_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(23)00001-3","article-title":"Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial","volume":"24","author":"Walter","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114129_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejca.2024.114129_bib9","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/170496","article-title":"Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas","volume":"2012","author":"Olsen","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"6","key":"10.1016\/j.ejca.2024.114129_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2024.114129_bib11","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114129_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.114129_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","article-title":"Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome","volume":"24","author":"Derks","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2024.114129_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114129_bib15","doi-asserted-by":"crossref","first-page":"6878409","DOI":"10.1155\/2018\/6878409","article-title":"Grading of neuroendocrine carcinomas: correlation of 68Ga-PET\/CT scan with tissue biomarkers","volume":"2018","author":"Liverani","year":"2018","journal-title":"Dis Markers"},{"key":"10.1016\/j.ejca.2024.114129_bib16","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.2147\/OTT.S91971","article-title":"First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrinecarcinoma","volume":"8","author":"Bongiovanni","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10.1016\/j.ejca.2024.114129_bib17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.ejca.2024.114129_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1530\/EJE-18-0305","article-title":"Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms","volume":"179","author":"Grolmusz","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114129_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12022-019-9570-y","article-title":"MiRNA-3653 is a potential tissue biomarker for increased metastatic risk in pancreatic neuroendocrine tumours","volume":"30","author":"Gill","year":"2019","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114129_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1530\/ERC-18-0244","article-title":"Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing","volume":"26","author":"Panarelli","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114129_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000487326","article-title":"A comprehensive assessment of the role of mirnas as biomarkers in gastroenteropancreatic neuroendocrine tumors","volume":"107","author":"Malczewska","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"282","key":"10.1016\/j.ejca.2024.114129_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.ejca.2024.114129_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000457956","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification","volume":"105","author":"Perren","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2024.114129_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915299","article-title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","volume":"12","author":"McNamara","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114129_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced Gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114129_bib26","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/cas.14811","article-title":"Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci"},{"issue":"Suppl 4","key":"10.1016\/j.ejca.2024.114129_bib27","volume":"41","author":"Mcnamara","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114129_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.canlet.2016.12.017","article-title":"Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts","volume":"388","author":"Todeschini","year":"2017","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.ejca.2024.114129_bib29","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/tox.23625","article-title":"MiR-1246 is responsible for lung cancer cells-derived exosomes-mediated promoting effects on lung cancer stemness via targeting TRIM17","volume":"37","author":"Liu","year":"2022","journal-title":"Environ Toxicol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114129_bib30","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41598-022-06192-w","article-title":"Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.ejca.2024.114129_bib31","first-page":"1570","article-title":"miR-1290 is a potential prognostic biomarker in non-small cell lung cancer","volume":"7","author":"Mo","year":"2015","journal-title":"J Thorac Dis"},{"issue":"2","key":"10.1016\/j.ejca.2024.114129_bib32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/bjc.2013.320","article-title":"miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1","volume":"109","author":"Iwagami","year":"2013","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:09:27Z","timestamp":1747656567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924007858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":32,"alternative-id":["S0959804924007858"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114129","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114129"}}